Friday, October 31, 2025 4:09:44 AM
Moderna gains on report it held talks with at least one large drugmaker
Moderna rose 12% after a report that it has held talks with at least one large drugmaker on a deal of "significant scope," according to a STAT News report.
A takeover or a large partnership was on the table, according to the STAT News item on Thursday, which cited one person familiar with the discussions. The precise nature of the potential agreement was unclear.
Moderna didn't immediately respond to Seeking Alpha's request for comment.
Separately on Thursday, Moderna (MRNA) cancelled from a UBS Global Healthcare conference scheduled for Nov. 9 - Nov. 12 in Palm Beach Gardens, Florida. Moderna cancelled from the conference due to scheduling conflicts, according to an email viewed by Seeking Alpha.
https://seekingalpha.com/news/4511489-moderna-gains-on-report-it-held-talks-with-at-least-one-large-drugmaker
Moderna rose 12% after a report that it has held talks with at least one large drugmaker on a deal of "significant scope," according to a STAT News report.
A takeover or a large partnership was on the table, according to the STAT News item on Thursday, which cited one person familiar with the discussions. The precise nature of the potential agreement was unclear.
Moderna didn't immediately respond to Seeking Alpha's request for comment.
Separately on Thursday, Moderna (MRNA) cancelled from a UBS Global Healthcare conference scheduled for Nov. 9 - Nov. 12 in Palm Beach Gardens, Florida. Moderna cancelled from the conference due to scheduling conflicts, according to an email viewed by Seeking Alpha.
https://seekingalpha.com/news/4511489-moderna-gains-on-report-it-held-talks-with-at-least-one-large-drugmaker
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:57:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 01:47:23 PM
- Moderna Recognized by TIME as One of the World's Most Impactful Companies • ACCESS Newswire • 05/12/2026 09:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Moderna (MRNA) Shares Surge After U.S. Passenger Tests Positive for Hantavirus • IH Market News • 05/11/2026 10:38:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 10:06:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:06:08 PM
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 • ACCESS Newswire • 05/06/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 09:25:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/01/2026 08:10:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 03:44:50 PM
- Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates • ACCESS Newswire • 05/01/2026 10:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:30:03 PM
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate • ACCESS Newswire • 04/21/2026 11:01:00 PM
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting • ACCESS Newswire • 04/21/2026 02:00:00 PM
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 04/21/2026 01:40:00 PM
- Moderna to Present at Upcoming Conferences in May 2026 • ACCESS Newswire • 04/21/2026 11:00:00 AM
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting • ACCESS Newswire • 04/17/2026 07:00:00 PM
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 • ACCESS Newswire • 04/15/2026 11:00:00 AM
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 • ACCESS Newswire • 04/06/2026 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:45:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/16/2026 08:32:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 08:31:50 PM
